Johnson & Johnson is increasingly digitizing in the medical device space, with the company even recently rebranding the business to Johnson & Johnson MedTech to reflect the shift.

Many medtech companies have embraced the trend. It’s all about providing software, knowledge and insights to boost healthcare outcomes and hopefully help the system operate more efficiently — versus simply providing devices.

Not only is J&J transforming in-house, but it’s engaging in M&A to boost its offerings. MedTech’s EVP Ashley McEvoy said during the company’s Q1 earnings call: “We’re going to continue to do tuck-ins and to really digitize the patient experience.”

Come to DeviceTalks Boston, May 10-11, 2022, and hear a panel of top officials from J&J’s DePuy Synthes discuss how the company is evolving.

They’ll discuss how DePuy Synthes is changing its product development process, setting up a supply chain for a MedTech organization, learning about regulatory and access requirements for digital solutions, evolving its commercialization plans and using technology to amplify the effectiveness and reach of education solutions.

Panelists include:

  • Jennifer Dubord, end to end supply chain lead, Mitek Sports Medicine and Shoulder Reconstruction;
  • Therese Kelley director, WW education strategy & U.S. execution, DePuy Synthes Sports;
  • Kristine Christo, senior director, regulatory affairs, Mitek Sports Medicine and Shoulder Reconstruction;
  • Anita Barnick VP, R&D, Mitek Sports Medicine and Shoulder Reconstruction;
  • Rajit Kamal, worldwide president, sports medicine/shoulder reconstruction, DePuy Synthes.

Register today!